ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

MLTX MoonLake Immunotherapeutics

45,26
2,69 (6,32%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
MoonLake Immunotherapeutics MLTX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
2,69 6,32% 45,26 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
43,51 43,405 45,465 45,26 42,57
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
10.4.202413:00BWMoonLake Immunotherapeutics Inks Three-Year Technology..
11.3.202413:01EDGAR2Form 8-K - Current report
10.3.202417:00GLOBEMoonLake announces significant improvements with Nanobody®..
04.3.202414:00GLOBEMoonLake Immunotherapeutics to present MIRA trial data of..
01.3.202401:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202414:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29.2.202414:03EDGAR2Form 8-K - Current report
29.2.202414:00GLOBEMoonLake Immunotherapeutics Reports Full Year 2023 Financial..
26.2.202415:00EDGAR2Form 8-K - Current report
26.2.202414:00GLOBEMoonLake Immunotherapeutics Announces Positive Feedback from..
23.2.202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202400:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.2.202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202422:02EDGAR2Form 144 - Report of proposed sale of securities
15.2.202414:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:05EDGAR2Form 144 - Report of proposed sale of securities
21.12.202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:16EDGAR2Form 144 - Report of proposed sale of securities
19.12.202322:34EDGAR2Form 144 - Report of proposed sale of securities
14.11.202314:00GLOBEMoonLake Immunotherapeutics Reports Third Quarter 2023..
06.11.202313:55EDGAR2Form 8-K - Current report
05.11.202317:00GLOBEMoonLake Immunotherapeutics announces landmark Phase 2..
16.10.202312:16EDGAR2Form 8-K - Current report
15.10.202315:03GLOBEMoonLake Immunotherapeutics announces the full dataset from..
11.10.202316:15GLOBEMoonLake Immunotherapeutics presents positive 12-week data..
04.10.202313:01GLOBEPhase 2 MIRA primary analysis trial results (12-week) for..
06.9.202313:00GLOBEMoonLake Immunotherapeutics to host a Capital Markets Day on..
10.8.202313:00GLOBEMoonLake Immunotherapeutics Reports Second Quarter 2023..
25.7.202314:00GLOBEMoonLake completes patient randomization ahead of schedule..
17.7.202313:30IHMARKETNEWSMonday’s Wall Street Highlights: Microsoft, Santander,..
28.6.202311:00GLOBEMoonLake Immunotherapeutics Announces Pricing of $400..
26.6.202322:01GLOBEMoonLake Immunotherapeutics Announces Proposed Underwritten..
25.6.202315:00GLOBEMoonLake Immunotherapeutics achieves landmark milestone with..
12.5.202313:45GLOBEMoonLake Immunotherapeutics Reports First Quarter 2023..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock